William Corrao, MD
Pulmonary Disease · Warwick, RINPI 1033132816
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $148,875 of the $166,211 with a category attached, or 89.6%. GSK accounts for 81.3% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $58,770 and has fallen 99.9% since, to $30 in 2025. Among pulmonary disease clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 227 payments — averaging $732.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$135K
- Boehringer Ingelheim$30K
- Regeneron Healthcare Solutions, Inc.$258
- Sanofi$217
- Novartis$78
- Mylan Specialty L.p.$74
- plus $381 from 9 others
What the payments were for
- Consulting fees$6,5004%
- Speaking & faculty fees$148,87590%
- Travel & lodging$5,1213%
- Food & beverage$5,6123%
- Education$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 140 | $135,056 |
| Boehringer Ingelheim | 41 | $30,147 |
| Regeneron Healthcare Solutions, Inc. | 6 | $258 |
| Sanofi | 9 | $217 |
| Novartis | 4 | $78 |
| Mylan Specialty L.p. | 4 | $74 |
| Grifols USA, LLC | 3 | $57 |
| AstraZeneca | 3 | $55 |
| Sunovion Pharmaceuticals Inc. | 7 | $54 |
| Actelion Pharmaceuticals US, Inc. | 3 | $53 |
| Jazz Pharmaceuticals Inc. | 2 | $48 |
| Insmed, Inc. | 1 | $37 |
| Merck | 1 | $30 |
| CSL Behring | 2 | $29 |
| United Therapeutics Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$63,061
- NUCALA$37,464
- OFEV$16,588
- ANORO$1,273
- AREXVY$125
- DUPIXENT$115
- ANORO ELLIPTA$112
How this compares
$166,211 in reported general payments places this provider in the 95th percentile of 59 pulmonary disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Warwick
- Thomas RaimondoWarwick$8K
- Anuradha RamaswamyWarwick$3K
- Elias JabbourWarwick$2K
- Stephen MatareseWarwick$2K
- Khalid AlhouraniWarwick$2K
- Ashish ThakkarWarwick$1K
- Neil LaboveWarwick$350
- Gerald WeinhouseWarwick$15
- Michael StanchinaEast Greenwich$219K
- Corey VentetuoloRiverside$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.